Transdermal Patch for TBI Neuropsychiatric Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective methods for preventing or alleviating neuropsychiatric symptoms and psychiatric disorders associated with traumatic brain injury (TBI) and related disorders, particularly with no FDA-approved medication-based therapies for acute stress reactions or cognitive symptoms.
Innovation Solution
A matrix-type transdermal patch containing opipramol, administered in effective dosages ranging from 5-500 mg per day, which can increase bioavailability by 20-50% to 5-fold compared to oral forms, and can be used alone or in combination with additional therapeutic agents to treat TBI-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral dosage form of opipramol is used, then the treatment is simple to administer, but the bioavailability is low (20-50% lower than transdermal)
Solution Approach 1:
The patent introduces the skin as an intermediary delivery route between oral administration and systemic circulation. The transdermal patch uses the skin's natural permeability to deliver opipramol directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism, thereby achieving higher bioavailability while maintaining ease of use through simple patch application.
Solution Approach 2:
The patent changes the administration route parameter from oral to transdermal. This parameter change fundamentally alters the pharmacokinetic profile of opipramol, increasing bioavailability by 20-50% while maintaining simplicity of administration through the user-friendly patch application process.
2Device complexity
If oral dosage form of opipramol is used, then the formulation is simple, but the drug delivery is not sustained
Solution Approach 1:
The patent segments the drug delivery process into controlled stages through the transdermal patch structure. The patch contains opipramol in a matrix that gradually releases the drug through the skin over an extended period, providing sustained delivery without requiring complex formulation changes to the active ingredient itself.
Solution Approach 2:
The transdermal patch enables continuous drug delivery through the skin, maintaining therapeutic levels of opipramol in the bloodstream over an extended period. This continuous delivery mechanism addresses the limitation of oral dosing intervals while avoiding the need for complex sustained-release oral formulations.
3Quantity of substance
If transdermal patch is used, then the bioavailability is increased (20-50% increase), but the device complexity increases
Solution Approach 1:
The patent employs a disposable transdermal patch that is applied once and removed after a set period. This disposable approach achieves high bioavailability through transdermal delivery while keeping the device relatively simple in structure. The patch is designed for single-use, eliminating the need for complex reusable components, storage systems, or adjustment mechanisms.
4Duration of action of moving object
If transdermal patch is used, then the drug delivery is sustained, but the manufacturing complexity increases
Solution Approach 1:
The transdermal patch utilizes a porous or semi-permeable matrix material that allows controlled diffusion of opipramol from the patch reservoir through the skin. This porous structure enables sustained drug delivery through passive diffusion gradients, achieving extended release without requiring complex manufacturing processes such as controlled-release coating applications or multi-layer lamination systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal patch effectively reduces neuropsychiatric symptoms and psychiatric disorders associated with TBI by increasing bioavailability and providing sustained drug delivery, offering a potential solution for treating TBI-related disorders with improved efficacy compared to oral administration.
Implementation Method 1
administering a matrix-type transdermal patch with a composition consisting of opipramol
Data Source
AI summary
The present invention relates to methods for the treatment or prevention of symptoms associated with traumatic brain injury (TBI) and related disorders. The present disclosure provides compositions and methods for preventing, ameliorating, or alleviating neuropsychiatric symptoms and psychiatric disorders associated with TBI and related disorders consisting of administering a matrix-type transdermal patch with a composition consisting of opipramol, excluding any other component such as a pharmaceutical carrier or excipient.